Karyopharm Therapeutics Inc. financial data

Symbol
KPTI on Nasdaq
Industry
Pharmaceutical Preparations
Location
85 Wells Avenue, Second Floor, Newton, MA
State of incorporation
DE
Fiscal year end
December 31
Latest financial report
10-Q - Q2 2024 - Aug 6, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 355 % -25.5%
Quick Ratio 4.87 % -24.4%
Debt-to-equity -273 % +49.8%
Return On Equity 66.9 % -67.7%
Return On Assets -38.7 % +17.1%
Operating Margin -89.9 % -4.85%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 125M shares +9.03%
Common Stock, Shares, Outstanding 125M shares +9%
Entity Public Float 201M USD -42.8%
Common Stock, Value, Issued 13K USD +8.33%
Weighted Average Number of Shares Outstanding, Basic 121M shares +5.97%
Weighted Average Number of Shares Outstanding, Diluted 154M shares +35.2%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 146M USD -0.23%
Research and Development Expense 149M USD +17.9%
Operating Income (Loss) -131M USD -4.61%
Nonoperating Income (Expense) 41.3M USD
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -89.6M USD +36.6%
Income Tax Expense (Benefit) 280K USD -6.36%
Net Income (Loss) Attributable to Parent -89.9M USD +36.5%
Earnings Per Share, Basic -0.83 USD/shares +43.2%
Earnings Per Share, Diluted -1.18 USD/shares +19.2%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 84.8M USD +4.8%
Inventory, Net 3.48M USD -5.34%
Other Assets, Current 31.5M USD
Assets, Current 209M USD -28.4%
Property, Plant and Equipment, Net 628K USD -18%
Operating Lease, Right-of-Use Asset 3.17M USD -40.1%
Assets 214M USD -28.2%
Accounts Payable, Current 2.8M USD +22.3%
Employee-related Liabilities, Current 16.5M USD -15.9%
Accrued Liabilities, Current 49.8M USD -3.86%
Liabilities, Current 57.6M USD -2.22%
Operating Lease, Liability, Noncurrent 955K USD -78.8%
Other Liabilities, Noncurrent 4.28M USD +75.8%
Liabilities 346M USD -6.22%
Accumulated Other Comprehensive Income (Loss), Net of Tax -605K USD +22.7%
Retained Earnings (Accumulated Deficit) -1.5B USD -6.37%
Stockholders' Equity Attributable to Parent -132M USD -85.5%
Liabilities and Equity 214M USD -28.2%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -43.7M USD -131%
Net Cash Provided by (Used in) Financing Activities 0 USD -100%
Net Cash Provided by (Used in) Investing Activities 21.9M USD
Common Stock, Shares Authorized 400M shares 0%
Common Stock, Shares, Issued 125M shares +9%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -21.8M USD +57.5%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 85.1M USD +3.99%
Deferred Tax Assets, Valuation Allowance 412M USD +8.62%
Deferred Tax Assets, Gross 1.03M USD -32%
Operating Lease, Liability 6.1M USD -32%
Depreciation 85K USD -70.7%
Payments to Acquire Property, Plant, and Equipment 195K USD
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -89.7M USD +36.7%
Lessee, Operating Lease, Liability, to be Paid 6.74M USD -35.6%
Property, Plant and Equipment, Gross 7.17M USD -7.88%
Operating Lease, Liability, Current 3.55M USD +14.9%
Lessee, Operating Lease, Liability, to be Paid, Year Two 2.92M USD -23.6%
Lessee, Operating Lease, Liability, to be Paid, Year One 3.82M USD +2.66%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 638K USD -57%
Lessee, Operating Lease, Liability, to be Paid, Year Three 2.92M USD -23.6%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 5M shares 0%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance 0 USD
Share-based Payment Arrangement, Expense 20.6M USD -15.5%
Interest Expense 27.1M USD +15.2%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%